Madrigal to grapple with lack of awareness about NASH ahead of potential FDA approval
Madrigal Pharmaceuticals may be first in line to bring a NASH drug to market, but the company is also tasked with teaching Americans and their doctors about the little-known liver disease.
The FDA is set to decide whether to approve Madrigal’s resmetirom this week. An approval would represent a long-awaited success in a field where the current standard of care is diet and exercise — and a big market opportunity for Madrigal. An estimated 5% of Americans have NASH, which is also known as metabolic dysfunction-associated steatohepatitis (MASH). Jefferies analysts said in September that resmetirom could reach $3 billion in peak sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
